<DOC>
	<DOCNO>NCT00699348</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability once-monthly administration intravenous methoxy polyethylene glycolepoetin beta ( Mircera ) maintenance hemoglobin level hemodialysis participant chronic renal anemia . Participants currently receive intravenous epoetin alfa beta darbepoetin alfa receive intravenous Mircera start dose 120 , 200 360 micrograms/month ( base erythropoietin stimulating agent [ ESA ] dose administer week -1 ) . Subsequent dos adjust maintain hemoglobin level within target range 10 to12 gram per deciliter ( g/dL ) . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Monthly Intravenous C.E.R.A . ( Mircera ) Hemodialysis Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic renal anemia ; Continuous intravenous maintenance erythropoietin stimulate agent ( ESA ) treatment previous month ; Regular long term hemodialysis therapy mode dialysis &gt; =3 month . Transfusion red blood cell previous 2 month ; Significant acute chronic bleeding , overt gastrointestinal bleeding ; Active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>